Verona Pharma plc — Director's Dealing 2023

May 4, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2023-05-01

Reporting Person: ZACCARDELLI DAVID (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-05-01	Ordinary Shares	S	455536	$2.5759	Disposed	16887336	Direct

Footnotes

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction entered into on May 24, 2022 solely with the intent to cover taxes in connection with the vesting of certain previously reported Restricted Share Units.

F3: The price reported represents the sale price of the ADSs divided by eight (8).

F4: Consists of (i) 7,067,760 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 883,470 ADSs); and (ii) 9,819,576 Ordinary Shares underlying 1,227,447 ADSs.